Pyxis Oncology (NASDAQ:PYXS) Downgraded to Sell Rating by Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Several other research analysts have also weighed in on PYXS. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research report on Tuesday, March 24th. Stifel Nicolaus reduced their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. Finally, Royal Bank Of Canada decreased their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.48 on Friday. The business has a 50-day moving average of $1.46 and a two-hundred day moving average of $2.48. The firm has a market capitalization of $92.99 million, a PE ratio of -1.15 and a beta of 1.41. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $11.04 million for the quarter, compared to analysts’ expectations of $0.13 million. As a group, research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Trading of Pyxis Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Laurion Capital Management LP grew its stake in shares of Pyxis Oncology by 32.3% in the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock worth $5,516,000 after acquiring an additional 1,170,505 shares during the last quarter. Vanguard Group Inc. raised its stake in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after acquiring an additional 14,566 shares in the last quarter. 683 Capital Management LLC lifted its holdings in Pyxis Oncology by 69.9% during the 4th quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after purchasing an additional 366,910 shares during the last quarter. Jane Street Group LLC grew its position in Pyxis Oncology by 158.8% during the 4th quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after acquiring an additional 482,310 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Pyxis Oncology by 26.4% in the fourth quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock valued at $838,000 after buying an additional 152,044 shares during the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.